TB-500 Frag Peptide: The Complete Guide - Uses, Mechanism, Dosing, Safety & Research

Quick Facts

What TB-500 Frag Does & How It Works

What It Does - Functional Outcomes

• Accelerates healing of tendons, ligaments, muscle tissue, and surface wounds by driving cell migration to injury sites
• Reduces fibrotic scar formation at healing sites, promoting more organized tissue repair
• Promotes new blood vessel growth into poorly vascularized tissues, improving nutrient and oxygen delivery to damaged areas
• Suppresses pro-inflammatory signaling during the acute and subacute phases of tissue injury
• Protects cardiac tissue in preclinical post-infarction models by activating endogenous progenitor cells
• Supports neurological recovery in preclinical stroke and brain injury models
• Activates hair follicle stem cells as a secondary, off-target effect

How It Works - Mechanism of Action

Actin Sequestration and Cell Motility via LKKTET Motif (Evidence: In vitro)

Thymosin Beta-4 and its fragments bind G-actin (the monomeric building block of the cell's internal structural scaffolding) with high affinity, preventing premature polymerization and keeping actin available for rapid reorganization. The LKKTET hexapeptide within the Tbeta4 sequence is the domain responsible for this interaction. A dissociation constant of approximately 0.5 micromolar indicates tight, specific binding. Think of a dissociation constant as a measure of how firmly two molecules grip each other: the lower the number, the tighter the grip. This actin regulation directly enhances the ability of keratinocytes (skin repair cells), endothelial cells (blood vessel lining cells), and stem cells to migrate toward sites of tissue damage.

Angiogenesis via VEGF Upregulation (Evidence: In vitro, Animal)

TB-500 Frag promotes upregulation of VEGF (vascular endothelial growth factor, the primary signaling molecule that instructs the body to build new blood vessels) and its receptor expression in endothelial cells. This triggers the migration and proliferation of endothelial cells and the formation of new capillaries. The therapeutic relevance is sharpest in poorly vascularized tissues like tendons and ligaments, where blood supply is the primary limiting factor in natural healing. More capillaries to the injury site means faster delivery of the oxygen, nutrients, and repair cells that reconstruction requires.

Anti-Fibrotic Action through Ac-SDKP (Evidence: Animal; indirect human pharmacological support)

The Ac-SDKP tetrapeptide (the N-terminal fragment of Tbeta4) specifically inhibits TGF-beta1 (transforming growth factor beta-1, a signaling protein that drives the overproduction of scar tissue)-mediated fibroblast activation. TGF-beta1 signals fibroblasts to deposit excessive collagen, turning functional tissue into structural scar. By blocking this signaling, Ac-SDKP reduces net collagen deposition at healing sites and in organs undergoing fibrotic remodeling. The human pharmacological evidence here is indirect but meaningful: ACE (angiotensin-converting enzyme) is the enzyme that normally degrades Ac-SDKP. ACE inhibitors raise endogenous Ac-SDKP levels by three- to fourfold, with documented anti-fibrotic clinical correlates.

Cardiac Stem Cell Activation via ILK (Evidence: Animal)

Tbeta4 and its fragments activate cardiac progenitor cells through upregulation of ILK (integrin-linked kinase, a signaling protein that supports cell survival, migration, and contractile function in cardiac tissue). Think of ILK as a structural and communication bridge connecting the cell's internal scaffolding to the surrounding tissue environment. In mouse myocardial infarction models, this mechanism translated to reduced infarct size, improved left ventricular function, and enhanced cardiomyocyte survival.

Anti-Inflammatory Cytokine Modulation (Evidence: In vitro, Animal)

TB-500 Frag downregulates pro-inflammatory cytokines (signaling proteins that drive inflammation) including TNF-alpha (a protein that signals the immune system to increase inflammation), IL-1beta (interleukin-1 beta, another inflammatory signaling molecule), and IL-6 (interleukin-6, which amplifies the inflammatory response), while promoting anti-inflammatory mediators. This activity reduces the duration and magnitude of the inflammatory response at injury sites without fully suppressing the immune signaling that initiates repair. The net effect is a more controlled inflammatory phase that transitions more quickly to the proliferative and remodeling stages of healing.

TB-500 Frag Molecular Profile

Structure reference: View Thymosin Beta-4 on PubChem at pubchem.ncbi.nlm.nih.gov/compound/Thymosin-beta-4 - Publishing team: retrieve 2D structure image from this link.

TB-500 Frag Uses & Benefits

Tendon and Ligament Repair

TB-500 Frag is most commonly sought in community protocols for injuries to tendons and ligaments. Achilles tendon, rotator cuff, patellar tendon, and ligament sprains are the most frequently cited targets. The mechanism is directly relevant: tendons and ligaments have poor intrinsic blood supply, which is the primary reason they heal slowly under normal conditions. TB-500 Frag's angiogenic activity promotes new capillary formation into these tissues, while the actin-mediated cell migration enhancement drives repair cells to the injury site. Multiple rodent studies confirm accelerated healing in these tissue types, and community documentation of use for these injuries is extensive. (Evidence: Moderate: animal)

Muscle Injury Recovery

Muscle strains, tears, and post-surgical tissue healing represent a secondary application. The same angiogenic and cell migration mechanisms are relevant to accelerating the repair timeline. The anti-fibrotic Ac-SDKP activity is particularly relevant here: muscle injuries that heal with excessive scar tissue lose functional capacity. Reducing fibrotic deposition at healing sites is a meaningful quality-of-repair objective. Community protocols targeting muscle recovery often use TB-500 Frag in combination with BPC-157 to address both angiogenic stimulation and the fibrotic remodeling component simultaneously. (Evidence: Moderate: animal rodent models)

Anti-Fibrotic Applications

The Ac-SDKP component of TB-500 Frag has been studied specifically as an anti-fibrotic agent in cardiac, renal, and pulmonary fibrosis models. In each system, the mechanism is consistent: inhibition of TGF-beta1 (transforming growth factor beta-1)-driven fibroblast activation reduces pathological collagen deposition. This anti-fibrotic application is distinct from injury recovery. It targets chronic or systemic fibrotic processes rather than acute tissue repair. The indirect human evidence via ACE inhibitor pharmacology gives this application a stronger mechanistic basis than most peptide use cases. (Evidence: Moderate: animal; indirect human pharmacological support)

Cardiac Tissue Protection

The cardiac application of TB-500 Frag is grounded in some of the highest-quality preclinical work published for any peptide in this space. The cardiac stem cell activation findings published in Nature demonstrated reduced infarct size and improved ventricular function following Tbeta4 administration in post-MI mouse models. These represent the peak of the evidence base for this compound family. Community use for cardiovascular research contexts is limited and more experimental than the musculoskeletal applications, but the mechanistic rationale is legitimately strong. (Evidence: Moderate: animal)

Neurological Recovery

Preclinical stroke and traumatic brain injury models have demonstrated that Tbeta4 administration reduces infarct volume (the area of dead brain tissue), promotes neurogenesis (new brain cell growth), and supports oligodendrocyte differentiation (the process by which specialized cells mature to form the protective myelin sheath around nerve fibers) and remyelination. Community use for neurological recovery remains far less documented than musculoskeletal applications. The gap between preclinical findings and confirmed human neurological outcomes is substantial. Some combination protocols with neuroprotective peptides like Selank or Semax include TB-500 Frag as a complementary component. (Evidence: Preliminary: animal only)

Where This Guide Comes From

TB-500 Frag Results & Timelines

Soft Tissue Injury Recovery

• Week 1-2: Early effects, if noticed at all, tend to be subtle reductions in localized inflammation or pain sensitivity at the injury site. Most of the cellular-level activity during this phase is happening below the threshold of subjective perception.
• Week 3-4: The first noticeable functional improvements are commonly reported in this window. Reduced pain with movement, improved range of motion, and faster return to partial loading of the injured structure are the most frequently cited markers.
• Week 5-8: More substantive recovery milestones in this range: return to full functional activity in many cases for moderate injuries, with continued improvement for more significant injuries. The anti-fibrotic effects on healing tissue quality may continue accruing beyond the point where pain has resolved.
• Beyond 8 weeks: Chronic or severe injuries (partial tears, long-standing tendinopathies) tend to require extended protocols or repeated courses. The remodeling process continues well after the active peptide administration phase ends.

Inflammation and Systemic Anti-Fibrotic Goals

• Week 1-3: Reductions in perceived inflammatory symptoms (joint swelling, chronic pain) are sometimes reported within the first two to three weeks for users targeting systemic anti-inflammatory effects.
• Week 4-8: Continued improvement in chronic inflammatory markers or tissue quality. Anti-fibrotic effects at the extracellular matrix level are not directly perceptible in real time. They manifest over time as improved functional quality of healing tissue rather than acute symptom resolution.

Cardiovascular and Neurological Contexts

• Community documentation for these applications is sparse compared to musculoskeletal use. Timeline expectations for cardiac or neurological applications are extrapolated from preclinical models rather than well-documented community protocol data, and should be understood as highly uncertain.

How to Administer TB-500 Frag

Subcutaneous Injection (SubQ)

Subcutaneous injection is the most commonly documented administration route for TB-500 Frag in community protocols. The abdominal region is most frequently cited as the preferred injection site due to ease of access and consistent subcutaneous tissue depth. SubQ injection offers reliable systemic absorption, is relatively comfortable with proper technique, and is consistent with how the parent compound Thymosin Beta-4 has been administered in preclinical research. This is the default route for the vast majority of documented TB-500 Frag use.

Intramuscular Injection (IM)

Intramuscular injection is used by some community practitioners, sometimes with the rationale of achieving faster absorption or localized delivery near the injury site. There is no pharmacokinetic data specific to TB-500 Frag comparing subcutaneous versus intramuscular bioavailability or onset in humans. Some protocols cite localized IM injection near the injury site as theoretically preferred for concentrated local delivery, but formal research support for this approach does not exist. SubQ remains the better-documented and more commonly used route.

Oral

Oral administration of TB-500 Frag is not effective. Peptides are degraded by proteases (digestive enzymes that break down proteins) in the gastrointestinal tract and gastric acid before systemic absorption can occur. The Ac-SDKP tetrapeptide, the shortest active fragment, is particularly susceptible to rapid hydrolysis under gastric conditions. No oral formulations of TB-500 Frag are used in any documented research or community protocol. Administration is exclusively by injection.

TB-500 Frag Dosage & Cycle Length

Overall dosing range: 1.0-2.5 mg per injection, typically twice per week. Range varies by goal, phase of protocol, and individual response.

How the goal shifts where you land:

• Low end of range (1.0 mg per injection): Associated with maintenance and anti-inflammatory protocols, longer ongoing cycles where lower total dose over time is the priority
• Mid range (1.5-2.0 mg per injection): The most commonly documented range in community protocols, used for general soft tissue injury recovery and the majority of documented use cases
• High end of range (2.0-2.5 mg per injection): Sometimes used during initial phases or for acute injury contexts (evidence grade: Anecdotal / community-reported; no human dose-escalation trials exist)

Frequency: Twice weekly is the most consistently documented frequency across community protocols. Some protocols cite once weekly for later phases after an initial period of more frequent dosing.

Cycle length: Typically 4-8 weeks total, with off-cycle periods between courses. Extended protocols running to 12 weeks are noted in some community logs, particularly for chronic injuries or ongoing anti-fibrotic goals.

TB-500 Frag vs. full TB-500 dosing context: Community discussions suggest that the TB-500 Frag peptide may warrant somewhat lower total doses than the full 43-amino acid TB-500 compound, given the theoretical concentration of bioactive sequences. However, this differentiation is based on community reasoning rather than comparative pharmacokinetic data. No head-to-head dosing studies exist.

TB-500 Frag Vial Sizes, Costs & Quality

Common vial sizes: 2 mg (most common), 5 mg, 10 mg

Typical cost range: $45-$180 per vial for U.S.-manufactured research-grade peptides at current market pricing. Varies by vial size, supplier, and verified purity level. Smaller 2 mg vials typically fall in the $45-$75 range; 5 mg vials in the $80-$120 range; 10 mg vials in the $130-$180 range.

Storage: lyophilized (dry powder):

• Temperature: Refrigerate below 4 degrees C for routine storage; freeze for long-term storage beyond 3-6 months
• Shelf life: Typically 12-24 months from manufacture when properly stored in lyophilized form
• Light sensitivity: Protect from direct light; amber or opaque vials are standard for this reason

Storage: reconstituted (in solution):

• Temperature: Requires refrigeration at 2-8 degrees C after reconstitution
• Use window: Typically 14-28 days once reconstituted, depending on reconstitution solvent and storage conditions

Normal appearance after reconstitution: TB-500 Frag dissolves into a clear, colorless to very slightly yellow-tinted aqueous solution. Full dissolution is expected. The peptide is water-soluble and does not require acetic acid for reconstitution, unlike some other research peptides. A fully transparent solution after mixing is normal.

Signs of degradation: Heavy cloudiness or milky opacity beyond what mixing turbulence causes, visible particulates or aggregates that do not dissolve with gentle agitation, unusual discoloration beyond very faint yellow, or any off-odor. Degraded solution should not be used.

Quality Considerations

The gap between high-quality and low-quality TB-500 Frag is larger than for most research peptides. "TB-500 Frag" lacks a standardized molecular definition. This means suppliers can claim the designation while selling products of widely varying sequence composition, purity, and verification status. What gets cut when pricing drops well below market norms is typically the peptide synthesis quality, the purification step (HPLC purification is expensive), and the third-party testing that generates a certificate of analysis with actual mass spectrometry confirmation. A CoA (certificate of analysis) from a credible independent laboratory is not just paperwork: it is the only way a buyer can verify that the sequence in the vial matches what is on the label. U.S.-manufactured research peptides come with documented synthesis processes, third-party analytical testing, and domestic accountability that overseas suppliers operating without oversight cannot offer. For a compound where the specific fragment composition matters to the mechanism, knowing what is actually in the vial is not optional.

TB-500 Frag Side Effects & Safety

Side Effect Spectrum

Contraindications

• Active malignancy: TB-500 Frag promotes cell migration and angiogenesis. Both processes could theoretically support tumor growth in people with existing cancer. This is a theoretical concern based on mechanism rather than confirmed oncological evidence in humans, but the community consensus and preclinical reasoning both point strongly toward avoiding use in anyone with active or recent cancer.
• Personal or close family history of cancer: Flagged as a caution in most community-facing guidance due to the pro-angiogenic mechanism. The evidence basis is theoretical, not confirmed.
• Active systemic infection: Pro-angiogenic and cell migration-enhancing effects are a theoretical concern in the context of active infection; insufficient data exists to confirm safety.
• Known hypersensitivity to any component: Standard contraindication for any injected compound.
• Concurrent use of ACE inhibitors: Ac-SDKP is normally degraded by ACE (angiotensin-converting enzyme). ACE inhibitors raise endogenous Ac-SDKP levels. The interaction between exogenous Ac-SDKP-containing fragments and ACE inhibitor-induced Ac-SDKP elevation is not studied. Theoretical additive or unpredictable effects warrant caution.

Populations Where Caution Is Warranted

• Pregnancy and breastfeeding: Insufficient safety data; use is not recommended without medical supervision
• Pediatric use: Not studied in pediatric populations; not appropriate without medical supervision
• Individuals with autoimmune conditions: The anti-inflammatory and immune-modulating properties of TB-500 Frag are not characterized in the context of autoimmune disease; theoretical concern that immune modulation could affect disease activity
• Individuals on immunosuppressive therapy: Complex interaction potential; insufficient data

Red Flags - Stop Use and Seek Medical Attention If:

• Significant swelling, warmth, or redness at the injection site that spreads or does not resolve within 48-72 hours
• Systemic allergic reaction signs: hives, difficulty breathing, significant swelling away from the injection site
• Unexplained pain or abnormal sensations at or near known or unknown masses in the body
• Severe or persistent headache, vision changes, or neurological symptoms not present before use
• Any symptom that is new, rapidly worsening, or unexplained that coincides with use

Drug and Compound Interactions

No peer-reviewed clinical interaction data exists for TB-500 Frag specifically. The most clinically relevant theoretical interaction is with ACE inhibitors: since Ac-SDKP is metabolized by ACE, ACE inhibitors reduce its breakdown and raise endogenous levels. Administering exogenous Ac-SDKP-containing fragments alongside ACE inhibitors could produce additive or unpredictable effects on fibrotic pathways and blood pressure-related signaling. TGF-beta1 (transforming growth factor beta-1) inhibitors, anti-inflammatory biologics, and other immunomodulatory agents represent additional theoretical interaction categories with no documented data. Community practice with BPC-157 combinations is common, but no interaction data exists for this combination either.

TB-500 Frag Research & Studies

Pharmacokinetics & Metabolism

Absorption & Bioavailability Published pharmacokinetic data specifically for TB-500 Frag administered by injection in humans does not exist. What is understood comes from preclinical work on the parent compound Thymosin Beta-4 and from the indirect pharmacological evidence surrounding Ac-SDKP. Thymosin Beta-4 is known to be systemically bioavailable after injection based on its documented effects in animal models at administered doses. The Ac-SDKP fragment's bioavailability is understood through its behavior as an endogenous peptide: it circulates in plasma at measurable levels, rises predictably with ACE inhibition, and has a documented half-life in that context.

Distribution Thymosin Beta-4 is one of the most abundant intracellular proteins in nucleated mammalian cells and distributes broadly across tissues including cardiac muscle, brain, kidney, and liver in animal models. Whether injected TB-500 Frag fragments concentrate preferentially in any specific tissue type has not been characterized in published data. The Ac-SDKP fragment circulates in plasma and is present in tissues that express ACE (angiotensin-converting enzyme), which is the primary enzyme responsible for its degradation.

Half-Life For Ac-SDKP specifically, plasma half-life is estimated to be short: in the range of minutes to a few hours under endogenous conditions, though exogenous administration alters this. For full Thymosin Beta-4, preclinical half-life estimates suggest a longer circulating duration, but this has not been directly measured in humans following systemic injection. The half-life for commercially available TB-500 Frag as administered is essentially unknown in human pharmacokinetic terms.

Metabolism & Elimination Ac-SDKP is primarily metabolized by ACE, which cleaves the peptide and deactivates it. This is the mechanistic basis for why ACE inhibitors raise endogenous Ac-SDKP levels so reliably. Larger fragments and the full Tbeta4 molecule are broken down by serine proteases (enzymes that cut proteins at specific sites) and aminopeptidases (enzymes that trim amino acids from the ends of peptide chains). Elimination of the resulting amino acid components is primarily renal.

Mechanistic Research

Actin-Binding and Cell Migration (Evidence: In vitro)

The binding interaction between Thymosin Beta-4 and G-actin has been rigorously characterized at a molecular level. The LKKTET hexapeptide within the Tbeta4 sequence is the domain responsible for this interaction, binding with a dissociation constant of approximately 0.5 micromolar. This indicates high-affinity binding that effectively sequesters actin monomers and prevents premature polymerization. In cell migration assays, both full Tbeta4 and isolated actin-binding fragments increased the rate of keratinocyte and endothelial cell migration by statistically significant margins compared to controls .

Angiogenesis via VEGF Pathway (Evidence: In vitro, Animal)

Multiple studies demonstrate Thymosin Beta-4's ability to upregulate VEGF (vascular endothelial growth factor) and VEGF receptor expression in endothelial cells, promoting tube formation and capillary sprouting in angiogenesis assays. In vivo, the Matrigel plug assay (a standard preclinical test of angiogenic activity) shows robust new vessel formation following Tbeta4 administration . This pro-angiogenic effect is particularly relevant to tissue repair in poorly vascularized structures like tendons, where blood supply is the rate-limiting step in natural healing.

Anti-Fibrotic Action of Ac-SDKP (Evidence: Animal, with indirect human pharmacological support)

Ac-SDKP has been repeatedly studied as an anti-fibrotic mediator across organ systems. In rodent models of cardiac fibrosis, Ac-SDKP administration reduced collagen deposition by inhibiting TGF-beta1 (transforming growth factor beta-1)-mediated fibroblast activation. Similar anti-fibrotic effects have been demonstrated in renal and pulmonary fibrosis models . The clinical observation that ACE inhibitor therapy raises endogenous plasma Ac-SDKP levels by three- to fourfold, and that this elevation correlates with reduced fibrosis in cardiovascular disease, provides indirect human-relevant evidence for this pathway's activity.

Cardiac Stem Cell Activation via ILK (Evidence: Animal)

The landmark paper by Bock-Marquette and colleagues demonstrated that systemic Tbeta4 administration following experimental myocardial infarction in mice activated cardiac progenitor cells through upregulation of ILK (integrin-linked kinase). This activation promoted cardiomyocyte survival, reduced infarct size, and improved left ventricular function compared to vehicle-treated controls . This remains among the highest-quality preclinical work published for any peptide in this compound class, appearing in one of the most rigorous peer-reviewed journals in science.

Neuroprotection in Stroke Models (Evidence: Animal)

In rat middle cerebral artery occlusion models (the standard preclinical stroke model), Tbeta4 administration reduced brain infarct volume, improved neurological outcome scoring, and promoted neurogenesis and angiogenesis in the peri-infarct zone. Oligodendrocyte differentiation (the maturation of cells that wrap nerve fibers in protective myelin) was also promoted in some experimental contexts. These findings generated legitimate scientific interest in Tbeta4 for neurological repair applications, though no translation to human systemic injection trials has occurred for this indication.

Condition-Focused Research

Musculoskeletal and Soft Tissue Repair {#research-tissue}

Rodent excisional wound models have consistently demonstrated accelerated re-epithelialization and reduced wound closure time with Tbeta4 and its active fragments . Studies showed increased keratinocyte and endothelial cell migration at wound sites following Tbeta4 treatment. In tendon and ligament models, reduced fibrotic scarring at healing sites and enhanced stem cell recruitment have been reported. These findings are coherent across multiple independent research groups and animal models, which strengthens the preclinical signal even in the absence of human systemic injection trials. (Evidence: Animal)

Cardiac Repair {#research-cardiac}

The myocardial infarction work published by Bock-Marquette et al. in Nature (2004) remains the landmark reference for this application . Systemic Tbeta4 administration improved survival, reduced infarct size, and enhanced cardiac function in post-MI mouse models. Subsequent work confirmed ILK as a key mediator and extended findings to cardiac fibrosis models, where Ac-SDKP specifically reduced collagen deposition. RegeneRx pursued clinical development of Tbeta4-based ophthalmic treatments and reached Phase 2/3 human trials for dry eye and neurotrophic keratopathy, representing the most advanced human clinical data available for any Tbeta4-based compound. (Evidence: Animal for cardiac; limited human for ophthalmic)

Anti-Fibrotic Applications {#research-antifibrotic}

Ac-SDKP's anti-fibrotic role has been studied across cardiac, renal, and pulmonary fibrosis models with consistent mechanistic findings: inhibition of TGF-beta1 (transforming growth factor beta-1)-driven fibroblast activation and reduction in net collagen deposition . The pharmacological observation that ACE inhibitors raise Ac-SDKP levels by three- to fourfold in humans, with documented anti-fibrotic clinical correlates, provides the most meaningful indirect human evidence available for this pathway. Whether exogenous Ac-SDKP administration replicates this effect at clinically meaningful levels in humans has not been tested in controlled trials. (Evidence: Animal; indirect human pharmacological evidence)

Ophthalmic and Wound Healing - Human Data {#research-ophthalmic}

The most direct human clinical data for a Tbeta4-based compound comes from RegeneRx's Phase 2/3 trials of RGN-259, a Tbeta4 ophthalmic solution . Trials for dry eye syndrome and neurotrophic keratopathy demonstrated statistically significant improvements in some endpoints, including symptom scores and corneal repair markers. This is topical rather than systemic administration and addresses ophthalmic indications rather than the musculoskeletal or cardiac uses that community interest centers on. However, it confirms that the parent compound's healing mechanisms are biologically active in humans in at least one delivery context. (Evidence: Human: Phase 2/3 ophthalmic trials)

Safety & Tolerability Research

Preclinical safety profiling for Thymosin Beta-4 across multiple species has not identified organ toxicity, mutagenicity, or teratogenicity at therapeutic doses. The compound has high endogenous concentrations (platelet Tbeta4 levels are in the range of 560 micrograms per billion platelets), which suggests the body is equipped to manage this molecule at physiological concentrations without adverse sequelae. RegeneRx's ophthalmic clinical trials reported good tolerability with minimal adverse events for topical application. Published clinical safety data for systemic injection in humans at community-used doses does not exist. The tumor promotion concern remains the most discussed theoretical risk, based on the pro-angiogenic and cell migration-promoting mechanisms rather than any confirmed oncological signal in clinical use. (Evidence: Animal; limited human for topical route)

Research Limitations

TB-500 Frag has a fundamental research limitation that goes beyond incomplete data: the compound itself lacks a standardized molecular definition in the published literature. Unlike named pharmaceutical compounds with fixed sequences and IND status, "TB-500 Frag" as sold in the research peptide market varies in exact composition between suppliers. This makes cross-study comparison and systematic evidence accumulation structurally difficult. No human clinical trials have been conducted using the specific commercial TB-500 Frag designation.

All human-relevant mechanistic and safety evidence is extrapolated from the parent compound Thymosin Beta-4 and the separately studied Ac-SDKP fragment. The longest available human safety data comes from ophthalmic applications, not systemic injection. No pharmacokinetic data (half-life, bioavailability, tissue distribution) exists from human injection studies. The absence of any dose-escalation or dose-finding human trial means the commonly used community dose ranges have no clinical validation whatsoever.

Is TB-500 Frag Legal? Regulatory & Sports Status

FDA status: TB-500 Frag is not approved for human use by the FDA for any indication. It has not received Investigational New Drug (IND) status under the specific commercial designation "TB-500 Frag." This classification covers both the full TB-500 compound and its fragments.

Classification context: In the United States and most other jurisdictions, TB-500 Frag is classified as a research compound that has not been authorized for human use, diagnosis, treatment, or prevention of any disease or condition. It is not a scheduled controlled substance in the U.S., but it is not approved for human therapeutic use.

WADA / USADA status: Thymosin Beta-4 is explicitly listed on the WADA Prohibited List under Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics, specifically as a growth factor and growth factor modulator. The prohibition extends to "releasing factors, analogs, and fragments with similar chemical structure or biological activity." This language directly and unambiguously covers TB-500 Frag. The compound is banned at all times (both in-competition and out-of-competition) under WADA rules, meaning no off-season window exists in which competitive athletes may use it. USADA applies the same prohibition.

Detection: WADA-accredited laboratories have developed immunoassay and mass spectrometry-based detection methods for Tbeta4 and related compounds in urine and blood. The distinction between endogenous Thymosin Beta-4 and exogenously administered amounts is achievable given the significant quantitative difference between physiological levels and doping-range doses. Detection windows are not publicly specified, as this information is strategically withheld to prevent circumvention.

Country-specific notes: In Australia, Thymosin Beta-4 is a Schedule 4 substance under the Therapeutic Goods Act. Since no approved human product exists, it is effectively inaccessible through legal medical channels. The 2012-2013 Essendon Football Club doping saga in the Australian Football League brought TB-500 and Thymosin Beta-4 to sustained regulatory scrutiny in that country. In Canada and across the European Union, the compound is not approved for human use. Regulatory treatment varies by EU member state. In the United Kingdom, it is classified as an unlicensed medicine and is not approved for human use.

TB-500 Frag vs. Alternatives

Commonly Paired With - Synergistic Stacks

• TB-500 Frag + BPC-157: The most frequently documented peptide combination in community protocols, specifically for soft tissue injury recovery. BPC-157 works through different but complementary pathways. Its primary signaling route runs through VEGFR2, a switch on cell surfaces that, when triggered, tells the body to grow new blood vessels, along with nitric oxide modulation. TB-500 Frag contributes actin-mediated cell migration and Ac-SDKP anti-fibrotic activity. The combination targets the healing process from two different mechanistic angles simultaneously, and many community practitioners describe the two as the foundational injury recovery stack.

• TB-500 Frag + GHK-Cu: GHK-Cu (copper peptide) has documented roles in collagen synthesis, tissue remodeling, and its own anti-inflammatory signaling. Combining it with TB-500 Frag is discussed in contexts where ECM (extracellular matrix, the structural scaffolding surrounding cells) remodeling quality, not just speed of healing, is the priority. GHK-Cu may complement TB-500 Frag's anti-fibrotic activity by promoting organized collagen synthesis rather than disorganized scar formation.

• TB-500 Frag + Selank or Semax: Less common, documented in neurological recovery contexts where the cell migration and neuroprotective properties of TB-500 Frag and the cognitive and neuroprotective profiles of Selank or Semax are being targeted together. This is a more experimental combination with limited community documentation.

Alternatives - When Another Peptide May Be Considered

Full TB-500 Full TB-500 (the complete 43-amino acid Thymosin Beta-4 analog) is the most direct alternative. It covers all the mechanisms that TB-500 Frag targets and adds the complete sequence that includes domains not isolated in the fragment. The community reasoning for choosing the Frag over the full compound is the theoretical concentration of anti-fibrotic and targeted activity in the isolated sequences. If anti-fibrotic emphasis is not the primary goal, full TB-500 is the more established choice.

BPC-157 BPC-157 is the most common alternative when the primary goal is soft tissue injury recovery and a compound with a more extensive published evidence base is preferred. BPC-157 has more total published studies than the Thymosin Beta-4 family for musculoskeletal applications and has meaningful published data for gut healing and GI integrity that TB-500 Frag does not. The trade-off is that BPC-157 does not carry the Ac-SDKP anti-fibrotic mechanism or the cardiac stem cell activation research that distinguishes the TB-500 family.

GHK-Cu GHK-Cu is an alternative when the primary application is skin, tissue quality, or surface-level wound healing rather than deep soft tissue or systemic repair. It works through copper-dependent collagen synthesis pathways rather than actin regulation and angiogenesis, making it a different tool for somewhat overlapping territory. Topical application is documented for GHK-Cu in ways it is not for TB-500 Frag.

Comparison table:

Build Your TB-500 Frag Protocol

FAQs

What is TB-500 Frag?

TB-500 Frag is a synthetic peptide fragment derived from Thymosin Beta-4 (Tbeta4), a naturally occurring 43-amino acid protein involved in regulating cell movement, tissue repair, and the actin cytoskeleton (the internal structural framework of cells). Rather than using the full Thymosin Beta-4 sequence, TB-500 Frag isolates specific bioactive subsequences, most notably the Ac-SDKP tetrapeptide and the LKKTET actin-binding motif, targeting regenerative, anti-inflammatory, and anti-fibrotic mechanisms more specifically than the complete compound. It is classified as a research compound and is not approved for human use by the FDA or any comparable regulatory agency.

What does TB-500 Frag do?

TB-500 Frag promotes cell migration toward injury sites, stimulates new blood vessel formation (angiogenesis), reduces pro-inflammatory cytokine activity, and suppresses the TGF-beta1 (transforming growth factor beta-1) signaling that drives fibrotic scar formation, primarily through its Ac-SDKP component. In preclinical animal research, the parent compound Thymosin Beta-4 has demonstrated accelerated wound healing, soft tissue repair, cardiac tissue protection following infarction, and neuroprotection in stroke models. These effects have not been confirmed in human clinical trials for systemic injection.

How long does TB-500 Frag take to work?

In community protocols for soft tissue injury recovery, the first noticeable effects are typically reported in weeks 3-4, with more substantive recovery milestones occurring in the weeks 5-8 range. Earlier phases (weeks 1-2) may produce mild reductions in localized inflammation or pain, but most cellular-level activity during this phase is not directly perceptible. Chronic or severe injuries tend to take longer, and anti-fibrotic effects at the extracellular matrix level are not experienced as acute symptoms; they manifest over time as improved tissue quality.

What is the typical dose of TB-500 Frag?

Community protocols for TB-500 Frag most commonly document doses in the range of 1.0-2.5 mg per injection, administered twice per week. These ranges are derived from community protocol documentation rather than human clinical trials. Optimal dosing for this specific compound has not been established in controlled research, and the right protocol depends on individual health history, goals, body weight, and other compounds being used. Individual variation in response means the same dose can produce different results in different people.

Is TB-500 Frag legal?

In the United States, TB-500 Frag is legal to purchase and possess for research purposes but is not approved for human use. Most other jurisdictions maintain a similar classification. For competitive athletes, TB-500 Frag is banned under WADA's Prohibited List (Section S2), and this ban explicitly covers Thymosin Beta-4 fragments and analogs with similar biological activity. There is no off-season exemption. Users are responsible for understanding the specific regulatory framework in their country.

Can TB-500 Frag be taken orally?

No. Oral administration of TB-500 Frag is not effective. Peptides are broken down by proteases (digestive enzymes) in the gastrointestinal tract and gastric acid before they can be absorbed into the bloodstream in meaningful quantities. The Ac-SDKP tetrapeptide, the shortest active fragment in TB-500 Frag, is particularly susceptible to rapid hydrolysis under gastric conditions. No oral formulations of TB-500 Frag are used in research practice, and the compound is administered exclusively by injection (subcutaneous or intramuscular) in all documented protocols.

How does TB-500 Frag differ from full TB-500?

TB-500 Frag isolates specific bioactive subsequences from the full 43-amino acid Thymosin Beta-4 molecule, primarily the Ac-SDKP tetrapeptide and the LKKTET actin-binding region, rather than using the complete sequence. The theoretical advantage of the fragment is more targeted anti-fibrotic activity through the Ac-SDKP pathway, potentially with a different systemic activity profile. Full TB-500 engages all domains of the Tbeta4 molecule and has a somewhat larger (though still primarily preclinical) evidence base. No comparative human trials between TB-500 Frag and full TB-500 exist; the differentiation is based on mechanistic reasoning rather than direct experimental comparison.

Is TB-500 Frag banned in sport?

Yes, without qualification. Thymosin Beta-4 is listed on the WADA Prohibited List under Section S2, and the prohibition explicitly covers "releasing factors, analogs, and fragments with similar chemical structure or biological activity." TB-500 Frag falls directly under this language. WADA's prohibition does not require the fragment to be separately named for it to be banned. The ban applies at all times, both in-competition and out-of-competition, meaning there is no period during which competitive athletes subject to anti-doping rules may use this compound.

Does TB-500 Frag need to be refrigerated?

Yes. In lyophilized (freeze-dried powder) form, TB-500 Frag should be stored below 4 degrees C for routine storage, with freezing recommended for long-term storage beyond several months. Once reconstituted into solution, it must be refrigerated at 2-8 degrees C and used within approximately 14-28 days. The reconstituted solution should not be frozen. Exposure to heat, light, or repeated freeze-thaw cycles degrades the peptide and reduces potency.

What is the concern about TB-500 Frag and cancer?

The concern is theoretical and based on mechanism, not confirmed clinical evidence. TB-500 Frag promotes cell migration and angiogenesis: both processes that are essential for healing in injured tissue but that could theoretically support tumor growth by providing the blood supply and cellular mobility that expanding tumor masses require. Thymosin Beta-4 has been observed to be overexpressed in some cancer cell lines in laboratory studies. No confirmed cases of TB-500 or TB-500 Frag causing or accelerating cancer in clinical use have been published, but the precautionary guidance for individuals with active or recent cancer reflects this unresolved mechanistic concern.

Final Thoughts

TB-500 Frag occupies a specific and scientifically grounded position in the research peptide landscape. It is not a compound with a long list of confirmed human clinical outcomes; that would overstate what the evidence shows. What it is: a compound with a well-characterized biological mechanism derived from one of the most studied intracellular proteins in mammalian biology, a coherent preclinical evidence base across multiple independent research programs, and one distinctively documented feature. The Ac-SDKP fragment's anti-fibrotic activity has more indirect human-relevant support than most peptide mechanisms carry, through the ACE inhibitor connection. The cardiac stem cell work published in Nature, the ophthalmic human trials from RegeneRx, and the consistent wound healing data across independent animal research groups all point to a compound family that does something real. The honest framing is that what has been confirmed in animals and cell culture has not yet been tested in systemic injection human trials, and that gap matters.

The key cautions for anyone researching this compound are straightforward. The evidence base, while legitimate, is primarily preclinical. The commercially sold "TB-500 Frag" does not correspond to a single standardized molecule, which means quality and composition vary between suppliers in ways that matter for anyone trying to understand what they are actually working with. The WADA prohibition is complete and unambiguous for competitive athletes: there is no technical argument that TB-500 Frag is outside the prohibition, and the language of the Prohibited List was written to close exactly that loophole. The pro-angiogenic mechanism warrants genuine caution for anyone with a personal or family history of malignancy, not because harm has been confirmed, but because the mechanism makes the concern non-dismissible.

For anyone using MyPeptidePal to build a protocol, the research in this guide provides the foundation: what the compound does, where the evidence is strong, where it is limited, and what the safety considerations are. Turning that into an actual protocol requires mapping it against individual health history, goals, current health status, and other compounds in use. That personalization work is what the app is built to do, and the starting point is a clearer picture of the compound than most available resources provide.

References

1. Bock-Marquette, I., Saxena, A., White, M. D., DiMaio, J. M., & Srivastava, D. (2004). Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature, 432(7016), 466-472.

2. Malinda, K. M., & Goldstein, A. L. (1996). Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. The FASEB Journal, 10(13), 1502-1507.

3. Huff, T., Muller, C. S. G., Otto, A. M., Netzker, R., & Hannappel, E. (2001). beta-Thymosins, small acidic peptides with multiple functions. The International Journal of Biochemistry & Cell Biology, 33(3), 205-220.

4. Liu, J., Wang, Y., & Ouyang, X. (2012). Beyond angiotensin-converting enzyme inhibition: Renal protection from the Ac-SDKP peptide. Journal of the American Society of Hypertension, 6(5), 311-317.

5. RegeneRx Biopharmaceuticals. RGN-259 clinical program. ClinicalTrials.gov, identifiers NCT02293590 and related.

Additional sources pending editorial review.